|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L,
Teng F and Yu J: The predictive effect of the systemic
immune-inflammation index for patients with small-cell lung cancer.
Future Oncol. 15:3367–3379. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Frese KK, Simpson KL and Dive C: Small
cell lung cancer enters the era of precision medicine. Cancer Cell.
39:297–299. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755.
2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhan W, Liu Y, Gao Y, Gong R, Wang W,
Zhang R, Wu Y, Kang T and Wei D: RMI2 plays crucial roles in growth
and metastasis of lung cancer. Signal Transduct Target Ther.
5(188)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Go SI, Jeon H, Park SW, Kang MH, Kim HG
and Lee GW: Low pre-treatment nutritional index is significantly
related to poor outcomes in small cell lung cancer. Thorac Cancer.
9:1483–1491. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee SK, Song MJ, Kim SH and Park M:
Comparing various scoring system for predicting overall survival
according to treatment modalities in hepatocellular carcinoma
focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin
(ALBI) grade: A nationwide cohort study. PLoS One.
14(e0216173)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tsilimigras DI, Hyer JM, Moris D, Sahara
K, Bagante F, Guglielmi A, Aldrighetti L, Alexandrescu S, Marques
HP, Shen F, et al: Prognostic utility of Albumin-bilirubin grade
for short- and long-term outcomes after hepatic resection for
intrahepatic cholangiocarcinoma: A multi-institutional analysis of
706 patients. J Surg Oncol. 120:206–213. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kanda M, Tanaka C, Kobayashi D, Uda H,
Inaoka K, Tanaka Y, Hayashi M, Iwata N, Yamada S, Fujii T, et al:
Preoperative Albumin-bilirubin grade predicts recurrences after
radical gastrectomy in patients with pT2-4 gastric cancer. World J
Surg. 42:773–781. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Albers I, Hartmann H, Bircher J and
Creutzfeldt W: Superiority of the Child-pugh classification to
quantitative liver function tests for assessing prognosis of liver
cirrhosis. Scand J Gastroenterol. 24:269–276. 1989.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Johnson PJ, Berhane S, Kagebayashi C,
Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A,
Palmer D, et al: Assessment of liver function in patients with
hepatocellular carcinoma: A new evidence-based approach-the ALBI
grade. J Clin Oncol. 33:550–558. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhao S, Zhang T, Li H, Wang M, Xu K, Zheng
D, Du X and Liu L: Comparison of albumin-bilirubin grade versus
Child-Pugh score in predicting the outcome of transarterial
chemoembolization for hepatocellular carcinoma using time-dependent
ROC. Ann Transl Med. 8(538)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yagyu T, Saito H, Sakamoto T, Uchinaka EI,
Morimoto M, Amisaki M, Watanabe J, Tokuyasu N, Honjo S, Ashida K
and Fujiwara Y: Preoperative Albumin-bilirubin grade as a useful
prognostic indicator in patients with pancreatic cancer. Anticancer
Res. 39:1441–1446. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kinoshita F, Yamashita T, Oku Y, Kosai K,
Ono Y, Wakasu S, Haratake N, Toyokawa G, Takenaka T, Tagawa T, et
al: Prognostic impact of Albumin-bilirubin (ALBI) Grade on
Non-small lung cell carcinoma: A Propensity-score matched analysis.
Anticancer Res. 41:1621–1628. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB,
Peng JJ, Chen CQ, He YL and Cai SR: Systemic immune-inflammation
index for predicting prognosis of colorectal cancer. World J
Gastroenterol. 23:6261–6272. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cadwell JB, Afonso AM and Shahrokni A:
Prognostic nutritional index (PNI), independent of frailty is
associated with six-month postoperative mortality. J Geriatr Oncol.
11:880–884. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Racanelli V and Rehermann B: The liver as
an immunological organ. Hepatology. 43 (2 Suppl 1):S54–S62.
2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tuchendler E, Tuchendler PK and Madej G:
Immunodeficiency caused by cirrhosis. Clin Exp Hepatol. 4:158–164.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Albillos A, Lario M and Álvarez-Mon M:
Cirrhosis-associated immune dysfunction: Distinctive features and
clinical relevance. J Hepatol. 61:1385–1396. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Irvine KM, Ratnasekera I, Powell EE and
Hume DA: Causes and consequences of innate immune dysfunction in
cirrhosis. Front Immunol. 10(293)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Robinson MW, Harmon C and O'Farrelly C:
Liver immunology and its role in inflammation and homeostasis. Cell
Mol Immunol. 13:267–276. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Noor MT and Manoria P: Immune dysfunction
in cirrhosis. J Clin Transl Hepatol. 5:50–58. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lipschitz DA: Protein-energy malnutrition.
Hosp Pract (Off Ed). 23:87–99. 1988.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Harimoto N, Yoshizumi T, Sakata K, Nagatsu
A, Motomura T, Itoh S, Harada N, Ikegami T, Uchiyama H, Soejima Y
and Maehara Y: Prognostic significance of preoperative controlling
nutritional status (CONUT) score in patients undergoing hepatic
resection for hepatocellular carcinoma. World J Surg. 41:2805–2812.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tomita M, Ayabe T, Chosa E and Nakamura K:
Prognostic significance of pre- and postoperative glasgow
prognostic score for patients with non-small cell lung cancer.
Anticancer Res. 34:3137–3140. 2014.PubMed/NCBI
|
|
27
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444.
2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pinato DJ, Sharma R, Citti C, Platt H,
Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B,
et al: The albumin-bilirubin grade uncovers the prognostic
relationship between hepatic reserve and immune dysfunction in
HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther.
47:95–103. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Guo W, Cai S, Zhang F, Shao F, Zhang G,
Zhou Y, Zhao L, Tan F, Gao S and He J: Systemic immune-inflammation
index (SII) is useful to predict survival outcomes in patients with
surgically resected non-small cell lung cancer. Thorac Cancer.
10:761–768. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Thompson D, Perry LA, Renouf J, Vodanovich
D, Hong Lee AH, Dimiri J and Wright G: Prognostic utility of
inflammation-based biomarkers, neutrophil-lymphocyte ratio and
change in neutrophil-lymphocyte ratio, in surgically resected lung
cancers. Ann Thorac Med. 16:148–155. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Han Y, Wang J, Hong L, Sun L, Zhuang H,
Sun B, Wang H, Zhang X and Ren X: Platelet-lymphocyte ratio is an
independent prognostic factor in patients with ALK-positive
non-small-cell lung cancer. Future Oncol. 13:51–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jin Y, Zhao L and Peng F: Prognostic
impact of serum albumin levels on the recurrence of stage I
non-small cell lung cancer. Clinics. 68:686–693. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Nakagawa T, Toyazaki T, Chiba N, Ueda Y
and Gotoh M: Prognostic value of body mass index and change in body
weight in postoperative outcomes of lung cancer surgery. Interact
Cardiovasc Thorac Surg. 23:560–566. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tewari N, Martin-Ucar AE, Black E, Beggs
L, Beggs FD, Duffy JP and Morgan WE: Nutritional status affects
long term survival after lobectomy for lung cancer. Lung Cancer.
57:389–394. 2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Watanabe H, Yamada T, Komori K, Hara K,
Kano K, Takahashi K, Kumazu Y, Fujikawa H, Numata M, Aoyama T, et
al: Effect of prognostic nutrition index in gastric or
Gastro-oesophageal junction cancer patients undergoing nivolumab
monotherapy. In Vivo. 35:563–569. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yotsukura M, Ohtsuka T, Kaseda K, Kamiyama
I, Hayashi Y and Asamura H: Value of the glasgow prognostic score
as a prognostic factor in resectable non-small cell lung cancer. J
Thorac Oncol. 11:1311–1318. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:257–262. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shepshelovich D, Xu W, Lu L, Fares A, Yang
P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, et al: Body
Mass Index (BMI), BMI change, and overall survival in patients with
SCLC and NSCLC: A pooled analysis of the international lung cancer
consortium. J Thorac Oncol. 14:1594–1607. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kotoh Y, Saeki I, Yamasaki T, Sasaki R,
Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T, Takami T and
Sakaida I: Albumin-bilirubin score as a useful predictor of energy
malnutrition in patients with hepatocellular carcinoma. Clin Nutr.
40:3585–3591. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li N, Xu M, Cai MY, Zhou F, Li CF, Wang
BX, Ou W and Wang SY: Elevated serum bilirubin levels are
associated with improved survival in patients with curatively
resected non-small-cell lung cancer. Cancer Epidemiol. 39:763–768.
2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wen CP, Zhang F, Liang D, Wen C, Gu J,
Skinner H, Chow WH, Ye Y, Pu X, Hildebrandt MA, et al: The ability
of bilirubin in identifying smokers with higher risk of lung
cancer: A large cohort study in conjunction with global metabolomic
profiling. Clin Cancer Res. 21:193–200. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Otagiri M: A molecular functional study on
the interactions of drugs with plasma proteins. Drug Metab
Pharmacokinet. 20:309–323. 2005.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kragh-Hansen U, Chuang VT and Otagiri M:
Practical aspects of the ligand-binding and enzymatic properties of
human serum albumin. Biol Pharm Bull. 25:695–704. 2002.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ikeda S, Yoshioka H, Ikeo S, Morita M,
Sone N, Niwa T, Nishiyama A, Yokoyama T, Sekine A, Ogura T and
Ishida T: Serum albumin level as a potential marker for deciding
chemotherapy or best supportive care in elderly, advanced non-small
cell lung cancer patients with poor performance status. BMC Cancer.
17(797)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ito S, Ito H, Sato N, Hirayama Y, Kusakabe
T, Terui T and Ishitani K: Clinical factors associated with the
therapeutic outcome of chemotherapy in very elderly cancer
patients. Int J Clin Oncol. 24:596–601. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hsieh AH, Tahkar H, Koczwara B,
Kichenadasse G, Beckmann K, Karapetis C and Sukumaran S:
Pre-treatment serum lactate dehydrogenase as a biomarker in small
cell lung cancer. Asia Pac J Clin Oncol. 14:e64–e70.
2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pinato DJ, Sharma R, Allara E, Yen C,
Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, et al:
The ALBI grade provides objective hepatic reserve estimation across
each BCLC stage of hepatocellular carcinoma. J Hepatol. 66:338–346.
2017.PubMed/NCBI View Article : Google Scholar
|
